Wave reports Q3 2026 financial results and pipeline updates
Cash stands at $431 million with runway to 2Q 2028. WVE-006 regulatory planning advances, while GSK collaboration yields a $12 million milestone.
Latest Wave Life Sciences News & Updates
See the latest news and media coverage for Wave Life Sciences. We track all announcements, press releases, and industry mentions in real time, all in one place.
RNA medicines developer
wavelifesciences.com- Headquarters
- Cambridge, United States
- Founded year
- 2012
- Company type
- Public company
- Number of employees
- 380–500
- Industry
- Pharmaceuticals
Last updated
Latest news about Wave Life Sciences
In short: Wave Life Sciences reported a $12 million GSK milestone and advanced its WVE-006 regulatory pathway.
Company announcements
Wave Life Sciences plans a two-year registrational trial for WVE-006 in AATD following FDA alignment
The FDA supports a single trial design with interim analysis for accelerated approval and specific biomarker assays.
Wave Life Sciences receives $12 million from GSK for siRNA selection
GSK selects Wave's SpiNA siRNA candidate for hepatology indication. Three additional collaboration programs are advancing toward potential candidate selection.
Wave Life Sciences presents interim RestorAATion-2 trial data
The company shares preliminary WVE-006 efficacy findings for Alpha-1 antitrypsin deficiency at the European Respiratory Society Congress.
Media coverage
Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update
Planning underway for registrational trial of WVE-006 (RNA editing) in AATD, with an interim analysis for potential accelerated approval based on AATD biomarkers ...
Wave Gains FDA Support For WVE-006 Registrational Pathway In AATD
On Thursday, Wave Life Sciences said it reached alignment with the FDA on key aspects of the registrational pathway for WVE-006, an investigational RNA editing...
GSK selects siRNA candidate from Wave Life Sciences collaboration
GSK plc has selected a candidate from its research collaboration with Wave Life Sciences Inc. The selected candidate was developed using Wave's proprietary SpiNA design...
Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity - BioSpace
CAMBRIDGE, Mass., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.
Never miss news about Wave Life Sciences
Track Wave Life Sciences and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Wave Life Sciences competitors & trending companies
Browse news for competitors to Wave Life Sciences and other trending companies.
Moderna
Alnylam
QurAlis
Avidity Biosciences
SharkNinja
NRx
Ropes & Gray
HighTech Kaunas
inretrn
Poundland
Farrer & Co
Specialfastigheter
SISAB
Hemsö
Stenvalvet
Liljewall
Veidekke
Locum
NCC
Kriminalvården
Archus
Nyréns
Peab
MVB
VGR fastigheter
AIX
ByggDialog
Tengbom
LINK
Dynacon
Delphidata
Waystream
Netnod
Open Infra
PENN Entertainment
BrandCrowd